protocolSection,derivedSection,hasResults,annotationSection
"{'identificationModule': {'nctId': 'NCT03830788', 'orgStudyIdInfo': {'id': '2016-2-10-003'}, 'organization': {'fullName': 'Center Eugene Marquis', 'class': 'OTHER'}, 'briefTitle': 'Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy', 'officialTitle': 'Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy', 'acronym': 'TEMPOS'}, 'statusModule': {'statusVerifiedDate': '2025-07', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-10-04', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2030-04-04', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2031-04-04', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-01-31', 'studyFirstSubmitQcDate': '2019-02-04', 'studyFirstPostDateStruct': {'date': '2019-02-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-31', 'lastUpdatePostDateStruct': {'date': '2025-08-01', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Center Eugene Marquis', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly focused on the issue of erectile dysfunction. A total of 240 potent patients are randomized in two arms. The experimental arm consists of SBRT delivering 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. The control arm consists of brachytherapy by Iodine 125 delivering 144 Gy to the prostate. The main objective of this health economics study is to perform a cost-utility analysis of SBRT compared to ""standard"" Iodine 125 brachytherapy in low-risk prostate cancer, 3 years after treatment. The endpoint is the Incremental Cost-Utility Ratio (ICUR) between SBRT and brachytherapy as primary criterion, expressed in cost per quality adjusted life year (QALY) gained. Cost-effectiveness analyses are performed as secondary objective with Incremental Cost-Effectiveness Ratios (ICERs) expressed as cost per erectile dysfunction avoided and cost per Life Year Gained. A long term evaluation is also performed, including a cost-utility, cost-effectiveness and budget impact analysis at 5 years, a comprehensive assessment of the erectile dysfunction up to 5 years after treatment, an evaluation of acute and late genito-urinary (GU) and Gastro-Intestinal (GI) toxicities, and of quality of life up to 5 years after treatment.\n\nEight patients/year/center are expected to be recruited in 2 years in about twenty participating centers.\n\nIn total, to our knowledge, this study will be the first health economic evaluation which compares SBRT versus Iodine 125 brachytherapy in low risk and intermediate risk prostate cancer. Both cost-utility and cost-effectiveness analyses will also provide useful and complementary information to decision makers in order (i) to recommend the best strategy to adopt; (ii) to estimate the budget impact on the French National Health Insurance of the generalization of the cost-effective strategy. Finally, this study will allow to assess and compare accurately the erectile dysfunction after both treatment modalities.'}, 'conditionsModule': {'conditions': ['Prostate Cancer'], 'keywords': ['SBRT', 'brachytherapy', 'localized low-risk and intermediate risk prostate cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 240, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Brachytherapy', 'type': 'ACTIVE_COMPARATOR', 'description': 'radiation by brachytherapy: brachytherapy by Iodine 125 delivering 144 Gy to the prostate', 'interventionNames': ['Radiation: Radiation by brachytherapy']}, {'label': 'stereotactic body radiotherapy (SBRT)', 'type': 'EXPERIMENTAL', 'description': 'radiation by SBRT: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate. The prostate can be tracked/localized/treated thanks to the Cyberknife or a conventional linac equipped with an ExacTrac or a Calypso4D system.', 'interventionNames': ['Radiation: Radiation by SBRT']}], 'interventions': [{'type': 'RADIATION', 'name': 'Radiation by brachytherapy', 'description': 'Brachytherapy by Iodine 125 delivering 144 Gy to the prostate', 'armGroupLabels': ['Brachytherapy']}, {'type': 'RADIATION', 'name': 'Radiation by SBRT', 'description': 'SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.', 'armGroupLabels': ['stereotactic body radiotherapy (SBRT)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cost-utility analysis of SBRT compared to ""standard"" Iodine 125 brachytherapy', 'description': 'The cost-utility analysis is expressed in cost per quality adjusted life year (QALY) gained.', 'timeFrame': '3 years after treatment.'}], 'secondaryOutcomes': [{'measure': 'Cost-utility analysis of SBRT compared to ""standard"" iodine-125 brachytherapy', 'description': 'The cost-utility analysis is expressed in cost per quality adjusted life year (QALY) gained.', 'timeFrame': '5 years after treatment'}, {'measure': 'Cost-utility analysis of avoided erectile dysfunction cost', 'timeFrame': '3 and 5 years after treatment'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Main inclusion criteria\n\n* Biopsy proven prostate adenocarcinoma,\n* Low risk prostate cancer according to d'Amico (T1-T2a and PSA \\<10 ng/ml, and Gleason score 6) or intermediate risk prostate cancer according d'Amico but excluding tumor with Gleason score 7 (4 + 3),\n* Indication of a curative treatment by brachytherapy validated in multidisciplinary consultation meeting,\n\nMain exclusion criteria\n\n* Androgen deprivation therapy,\n* Contraindication for prostate Iodine 125 brachytherapy (Prostate volume \\> 50 cc, impossibility if general anesthesia).\n* Contraindication for Resonance Magnetic Imagery (RMI) (claustrophobia, pacemaker)\n* Participation to another research which could have an impact on the study treatment and the outcomes"", 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Martine Gestin, PhD', 'role': 'CONTACT', 'phone': '+33(0)299253036', 'email': 'm.gestin@rennes.unicancer.fr'}], 'overallOfficials': [{'name': 'Renaud De Crevoisier, PR', 'affiliation': 'Centre Eugène Marquis', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Clinique Claude Bernard', 'status': 'NOT_YET_RECRUITING', 'city': 'Albi', 'country': 'France', 'contacts': [{'name': 'Laurent Votron, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.9298, 'lon': 2.148}}, {'facility': 'ICO Paul Papin', 'status': 'RECRUITING', 'city': 'Angers', 'zip': '49055', 'country': 'France', 'contacts': [{'name': 'COLLIAUX Jérémy, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'facility': 'Institut Bergonié', 'status': 'NOT_YET_RECRUITING', 'city': 'Bordeaux', 'country': 'France', 'contacts': [{'name': 'Paul Sargos, MD', 'role': 'CONTACT'}, {'name': 'Paul Sargos', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'facility': 'Polyclinique Bordeaux-Aquitaine', 'status': 'RECRUITING', 'city': 'Bordeaux', 'country': 'France', 'contacts': [{'name': 'François Guichard, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'facility': 'CLCC Georges-François Leclerc', 'status': 'RECRUITING', 'city': 'Dijon', 'country': 'France', 'contacts': [{'name': 'Magali Quivrin, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'facility': 'Centre Amethys - Charlebourg - La Défense', 'status': 'RECRUITING', 'city': 'La Garenne-Colombes', 'zip': '92250', 'country': 'France', 'contacts': [{'name': 'BOSSI Alberto, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.90472, 'lon': 2.2469}}, {'facility': 'Centre de Cobalthérapie Hartman', 'status': 'NOT_YET_RECRUITING', 'city': 'Levallois-Perret', 'country': 'France', 'contacts': [{'name': 'Laurent Chauveinc, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.89389, 'lon': 2.28864}}, {'facility': 'CH Lyon Sud', 'status': 'TERMINATED', 'city': 'Lyon', 'country': 'France', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'facility': 'Institut régional du Cancer de Montpellier', 'status': 'NOT_YET_RECRUITING', 'city': 'Montpellier', 'country': 'France', 'contacts': [{'name': 'Carmen Llacer-Moscardo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'facility': 'Institut Curie', 'status': 'RECRUITING', 'city': 'Paris', 'zip': '75005', 'country': 'France', 'contacts': [{'name': 'CRÉHANGE Gilles, Pr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Hôpital Lyon Sud', 'status': 'TERMINATED', 'city': 'Pierre-Bénite', 'country': 'France', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'facility': 'Institut Jean Godinot', 'status': 'NOT_YET_RECRUITING', 'city': 'Reims', 'country': 'France', 'contacts': [{'name': 'Grégoire Bouché, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 49.26526, 'lon': 4.02853}}, {'facility': 'Centre Eugene Marquis', 'status': 'RECRUITING', 'city': 'Rennes', 'zip': '35042', 'country': 'France', 'contacts': [{'name': 'Renaud De Crevoisier, MD', 'role': 'CONTACT', 'phone': '+33 (0)2 99 25 30 31', 'email': 'r.de-crevoisier@rennes.unicancer.fr'}, {'name': 'Renaud De Crevoisier, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'facility': ""Centre d'oncologie et de radiothérapie Saint Jean"", 'status': 'RECRUITING', 'city': 'Saint-Doulchard', 'country': 'France', 'contacts': [{'name': 'FREDERIC-MOREAU Thomas, DR', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.10371, 'lon': 2.352}}, {'facility': ""Institut de Cancérologie de l'Ouest - Site Gauducheau"", 'status': 'RECRUITING', 'city': 'Saint-Herblain', 'country': 'France', 'contacts': [{'name': 'Stéphane Supiot, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}, {'facility': 'Institut de Cancérologie Lucien Neuwirth', 'status': 'NOT_YET_RECRUITING', 'city': 'Saint-Priest-en-Jarez', 'country': 'France', 'contacts': [{'name': 'Julien Langrand-Escure, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.4739, 'lon': 4.37678}}, {'facility': 'Institut Claudius Régaud', 'status': 'NOT_YET_RECRUITING', 'city': 'Toulouse', 'country': 'France', 'contacts': [{'name': 'Pierre Graff-Cailleaud, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'facility': 'CHU Tours - Hôpital Bretonneau', 'status': 'RECRUITING', 'city': 'Tours', 'country': 'France', 'contacts': [{'name': 'Gilles Calais, Pr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'facility': 'Institut de Cancérologie de Lorraine', 'status': 'RECRUITING', 'city': 'Vandœuvre-lès-Nancy', 'country': 'France', 'contacts': [{'name': 'Nicolas DEMOGEOT, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.66115, 'lon': 6.17114}}, {'facility': 'Gustave Roussy', 'status': 'RECRUITING', 'city': 'Villejuif', 'country': 'France', 'contacts': [{'name': 'Pierre Blanchard, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06950216', 'orgStudyIdInfo': {'id': 'KY-2025-007'}, 'organization': {'fullName': 'The Fourth Affiliated Hospital of Zhejiang University School of Medicine', 'class': 'OTHER'}, 'briefTitle': 'IONM During Radical Prostatectomy', 'officialTitle': 'Intraoperative Neuromonitoring During Radical Prostatectomy'}, 'statusModule': {'statusVerifiedDate': '2025-04', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-04', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-06', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-04-22', 'studyFirstSubmitQcDate': '2025-04-22', 'studyFirstPostDateStruct': {'date': '2025-04-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-22', 'lastUpdatePostDateStruct': {'date': '2025-04-30', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'The Fourth Affiliated Hospital of Zhejiang University School of Medicine', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'At present, the preferred treatment for patients with prostate cancer is still radical prostatectomy. Postoperative patients often face some complications, the most common complications include urinary incontinence and erectile dysfunction. Urinary incontinence is caused by intraoperative injury of urinary control nerves or muscles. Erectile dysfunction is related to intraoperative injury of nerves that control erection. Therefore, intraoperative nerve preservation is a key measure to reduce postoperative complications, especially to prevent erectile dysfunction. This study intends to improve the nerve-sparing radical prostatectomy by monitoring the nerve during radical prostatectomy, locating the cavernous nerve and other related nerves, in order to reduce the incidence of postoperative complications such as erectile dysfunction.'}, 'conditionsModule': {'conditions': ['Prostate Cancer'], 'keywords': ['Prostate cancer', 'Intraoperative neuromonitoring', 'Urinary incontinence', 'Erectile dysfunction']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'IONM group', 'type': 'EXPERIMENTAL', 'description': 'IONM was performed during the operation.', 'interventionNames': ['Other: IONM']}, {'label': 'control group', 'type': 'NO_INTERVENTION', 'description': 'No IONM'}], 'interventions': [{'type': 'OTHER', 'name': 'IONM', 'description': 'The probe needle electrodes were inserted into the corpus cavernosum penis, ischiocavernosus muscle, bulbocavernosus muscle, anal sphincter, etc., and each monitoring electrode was connected to the nerve monitor. The changes of electromyography of each effector during the operation were monitored in real time. The stimulation electrode was placed in the abdominal cavity during the operation. During the resection of the prostate, electrical stimulation was performed on the possible running area of the NVB, and the stimulation site where the signal was monitored was protected from resection and burning under the premise of safe surgery.', 'armGroupLabels': ['IONM group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'IIEF-5', 'description': 'international index of erectile function-5', 'timeFrame': '1,3,6 and 12 months after operation'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n\\- 1: Prostate cancer patients undergoing surgical treatment in our Hospital 2: Understand the content of this study, actively provide complete and true medical history and examination data, and be willing to cooperate with postoperative interviewers.\n\n3: Voluntarily participate in the study and sign the treatment document within the ethical framework.\n\nExclusion Criteria:\n\n* 1: Histopathology showed that the patient did not have prostate cancer 2: Use a cardiac pacemaker or other electromechanical prosthesis device 3: Suffering from a serious neurological disease, mental illness or other illness that may be life-threatening within two years', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Yichun Zheng, Doctor', 'role': 'CONTACT', 'phone': '0571-87783550', 'email': '2101090@zju.edu.cn'}], 'overallOfficials': [{'name': 'Yichun Zheng, Doctor', 'affiliation': 'The Fourth Affiliated Hospital Zhejiang University School of Medicine', 'role': 'STUDY_CHAIR'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}, {'id': 'D014549', 'term': 'Urinary Incontinence'}, {'id': 'D007172', 'term': 'Erectile Dysfunction'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D014555', 'term': 'Urination Disorders'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D059411', 'term': 'Lower Urinary Tract Symptoms'}, {'id': 'D020924', 'term': 'Urological Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}",False,
"{'identificationModule': {'nctId': 'NCT07048314', 'orgStudyIdInfo': {'id': 'Pro00039638'}, 'organization': {'fullName': 'The Methodist Hospital Research Institute', 'class': 'OTHER'}, 'briefTitle': 'Stem Cells for Erectile Dysfunction Post RALP', 'officialTitle': 'A Randomized Clinical Trial to Assess Safety and Efficacy of Allogeneic Adipose-derived Mesenchymal Stem Cells in Promoting the Recovery of Erectile Function Post Radical Retropubic Prostatectomy of Localized Prostate Cancer'}, 'statusModule': {'statusVerifiedDate': '2025-06', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-07-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-06-24', 'studyFirstSubmitQcDate': '2025-06-24', 'studyFirstPostDateStruct': {'date': '2025-07-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-06-24', 'lastUpdatePostDateStruct': {'date': '2025-07-02', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Brian Miles', 'investigatorTitle': 'MD', 'investigatorAffiliation': 'The Methodist Hospital Research Institute'}, 'leadSponsor': {'name': 'The Methodist Hospital Research Institute', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer.', 'detailedDescription': ""This is a prospective, single-center, double blind, four-arm, pilot study to evaluate safety and effectiveness of allogeneic stem cells promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer.\n\nAll participants will be assessed for eligibility Participants will be randomized in a 1:1:1:1 ratio to Arm 1, Arm 2, Arm 3 or Arm 4 using a validated system that automates the random assignment of participant numbers to randomization numbers.\n\nStudy participants will be randomized to receive either:\n\nArm 1 2.00x 10⁸ HB-adMSCCs locally injected into the corpora cavernosa of the penis and along the right and left neurovascular bundle of the penis in the OR at week 1 plus Placebo via IV in clinic at week 12.\n\nArm 2 Placebo locally injected into the corpora cavernosa of the penis and along the right and left neurovascular bundle of the penis in the OR at week 1 plus 2.00x 10⁸ HB-adMSCs via IV in clinic at week 12.\n\nArm 3 2.00x 10⁸ HB-adMSCs locally injected into the corpora cavernosa of the penis and along the right and left neurovascular bundle of the penis in the OR at week 1 plus 2.00x 10⁸ HB-adMSCs via IV in clinic at week 12.\n\nArm 4 Placebo locally injected into the corpora cavernosa of the penis and along the right and left neurovascular bundle of the penis in the OR at week 1 plus Placebo via IV in clinic at week 12.\n\nStudy Medication:\n\n1. Stem cells locally injected in the penis: subjects will receive 1.00x 10⁸ HB-adMSCs injection into the corpora cavernosa of the penis and 5.0x10⁷ HB-adMSCs along the right neurovascular bundle and 5.0x10⁷ HB-adMSCs along the left neurovascular bundle during surgery in the Operating Room (OR)\n2. Stem cells delivered intravenous: Subject will receive 2.00x10⁸ HB-adMSCs IV at the doctor's office.\n\nThe treatment duration will be 2 cycles. Treatment will be administered on Week 1 (in the OR) and on week 12 in the Urology Clinic.\n\nThe study duration will be 24 weeks post-surgery.""}, 'conditionsModule': {'conditions': ['Erectile Dysfunction', 'Prostate Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'FACTORIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1: allogeneic adipose-derived mesnchymal stem cells plus saline solution', 'type': 'EXPERIMENTAL', 'description': '2.00x 10⁸ HB-adMSCCs locally injected into the corpora cavernosa of the penis and along the right and left neurovascular bundle of the penis in the OR at week 1 plus Placebo via IV in clinic at week 12.', 'interventionNames': ['Drug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR', 'Drug: Placebo in clinic']}, {'label': '2: Placebo plus allogeneic adipose-derived mesnchymal stem cells', 'type': 'EXPERIMENTAL', 'description': '4 cc of saline solution in the corpora cavernosa of the penis and 4 cc of saline solution along the right and left neurovascular bundles of the penis in the OR at week 1 plus 2.00x 10⁸ HB-adMSCs via IV in clinic at week 12.', 'interventionNames': [""Drug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office"", 'Drug: Placebo in the OR']}, {'label': '3: allogeneic adipose-derived mesnchymal stem cells intra op and at week 12 in clinic', 'type': 'EXPERIMENTAL', 'description': '2.00x 10⁸ HB-adMSCs locally injected into the corpora cavernosa of the penis and along the right and left neurovascular bundle of the penis in the OR at week 1 plus 2.00x 10⁸ HB-adMSCs via IV in clinic at week 12.', 'interventionNames': [""Drug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office"", 'Drug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR']}, {'label': '4: placebo plus placebo', 'type': 'PLACEBO_COMPARATOR', 'description': '4 cc of saline solution in the corpora cavernosa of the penis and 4 cc of saline solution along the right and left neurovascular bundles of the penis in the OR at week 1 plus saline solutin via IV in clinic at week 12.', 'interventionNames': ['Drug: Placebo in the OR', 'Drug: Placebo in clinic']}], 'interventions': [{'type': 'DRUG', 'name': ""Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office"", 'description': ""2.00x10⁸ HB-adMSCs IV at the doctor's office."", 'armGroupLabels': ['2: Placebo plus allogeneic adipose-derived mesnchymal stem cells', '3: allogeneic adipose-derived mesnchymal stem cells intra op and at week 12 in clinic'], 'otherNames': ['HB-adMSCs']}, {'type': 'DRUG', 'name': 'Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR', 'description': '100 million stem cells (1.00x10⁸ HB-adMSCs) in the corpora cavernosa of the penis suspended in a 4 cc of sterile saline. 50 million stem cells (5.0x 10⁷ HB-adMSCs) along the right neurovascular bundle and 50 million cell (5.0x 10⁷ HB-adMSCs) along the left neurovascular bundle of the penis suspended in a 4 cc of sterile saline during the surgery', 'armGroupLabels': ['1: allogeneic adipose-derived mesnchymal stem cells plus saline solution', '3: allogeneic adipose-derived mesnchymal stem cells intra op and at week 12 in clinic'], 'otherNames': ['HB-adMSCs']}, {'type': 'DRUG', 'name': 'Placebo in the OR', 'description': '4 cc of saline solution in the corpora cavernosa of the penis and 4 cc of saline solution along the right and left neurovascular bundles of the penis during the surgery .', 'armGroupLabels': ['2: Placebo plus allogeneic adipose-derived mesnchymal stem cells', '4: placebo plus placebo'], 'otherNames': ['Saline solution in the OR']}, {'type': 'DRUG', 'name': 'Placebo in clinic', 'description': '30 mL syringe of the product should be mixed into a 250cc bag of sodium chloride solution 0.9% for infusion. should be administered intravenously, with a dosing rate of 4-5mL/min.', 'armGroupLabels': ['1: allogeneic adipose-derived mesnchymal stem cells plus saline solution', '4: placebo plus placebo'], 'otherNames': ['Saline solution in clinic']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in erectile function by IIEF', 'description': 'IIEF-5 is a tool to asses erectile dysfunction base on five questions about confidence, hardness, maintenance and satisfaction of erections. Score: 1 to 25.', 'timeFrame': 'from baseline to 6 months post treatment'}, {'measure': 'Change in erectile function by Epic 26', 'description': 'This questionnaire is designated to measure Quality of Life issues.Clinical relevance (\\>12 points) for sexual function domain score as measured by EPIC-26.', 'timeFrame': 'from baseline to 6 months post treatment'}, {'measure': 'Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs, Immune-Related Adverse Events (irAE)', 'description': 'AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.\n\nSAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during study and up to 70 days after last dose. IrAEs=AEs potentially associated with inflammation and considered to be causally related to study drug', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Change in urinary function', 'description': 'This questionnaire is designated to measure Quality of Life issues.Clinically relevant (≥9 points) difference in the EPIC-26 urinary incontinence domain score', 'timeFrame': 'from baseline to 6 months post treatment'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria:\n\n1. Patients scheduled for RALP with Dr. B. Miles at Houston Methodist.\n2. Men aged between 40 and 70 (inclusive) years old\n3. Localized prostate cancer: Clinical stage T1-T2, N0, M0\n4. Gleason score \\< 7\n5. Pre-op IIEF-5 \\>20 (Appendix A)\n6. Testosterone serum: \\> 300ng/dl with normal Free Testosterone\n7. Life expectancy of at least 10 years\n8. Performance status of ≤ 2 (Zubrod scale). (Appendix B)\n9. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with the policies of the institution\n10. Patient is willing to attempt intercourse at least 5 times per month following urinary control after surgery\n11. Supportive partner willing to complete sexual survey questionnaire (Appendix D)\n12. PDE5 inhibitors like sildenafil, tadalafil, vardenafil and avanafil are permitted pre and post-surgery if participant was taking this for ED at least 6 months before surgery.\n13. Patient need cardiac clearance by the cardiologist\n\nExclusion Criteria:\n\n1. Penile anatomical abnormalities (Peyronie's disease)\n2. Hypogonadism\n3. Any medication used for androgen ablation (e.g., LHRH agonist or antagonist, anti-androgens, etc.)\n4. Patients with AST levels above 40U/L ; ALT levels above 33 U/L and Glucose levels above 180 mg/dl and psychiatric disorders that require medication\n5. Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy or another investigational drug.\n6. Any previous penile implant or penile vascular surgery\n7. Injections of Trimix (combination of alprostadil, papaverine and phentolamine) pre and post-surgery .\n\n   \\-"", 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '40 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Houston Methodist', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007172', 'term': 'Erectile Dysfunction'}, {'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077330', 'term': 'Saline Solution'}, {'id': 'D000554', 'term': 'Ambulatory Care Facilities'}], 'ancestors': [{'id': 'D000077324', 'term': 'Crystalloid Solutions'}, {'id': 'D007552', 'term': 'Isotonic Solutions'}, {'id': 'D012996', 'term': 'Solutions'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}, {'id': 'D006268', 'term': 'Health Facilities'}, {'id': 'D005159', 'term': 'Health Care Facilities Workforce and Services'}]}}",False,
"{'identificationModule': {'nctId': 'NCT07273773', 'orgStudyIdInfo': {'id': 'RC2025_UNITED'}, 'organization': {'fullName': 'Rigicon, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction', 'officialTitle': 'Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) A Prospective, Multicenter, Single-Arm Performance-Goal Study', 'acronym': 'UNITED'}, 'statusModule': {'statusVerifiedDate': '2025-12', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2026-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-07', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2029-07', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-11-26', 'studyFirstSubmitQcDate': '2025-12-05', 'studyFirstPostDateStruct': {'date': '2025-12-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-24', 'lastUpdatePostDateStruct': {'date': '2025-12-29', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Rigicon, Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'descriptionModule': {'briefSummary': 'This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.', 'detailedDescription': 'Erectile dysfunction (ED) is a common male sexual dysfunction associated with a reduced quality of life for patients and their partners. Incidence of ED increases with age and is associated with depression, obesity, diabetes mellitus, hypertension, cardiovascular disease and benign prostatic hyperplasia. ED is diagnosed with symptoms of (1) inability to attain or sustain a penile erection during sexual activity and (2) a reduction of penile rigidity in \\>75% of sexual encounters during six months period. ED is estimated to affect approximately 52% of men in age of 40 to 70 years. It is projected in 2025, the worldwide ED prevalence of about 322 million. ED usually has organic causes, such as damage of arteries, smooth muscle and fibrous tissue. This results in impairment of blood flow to and from penis due to diabetes, renal disease, atherosclerosis and vascular disease.\n\nManagement of ED involves lifestyle modification, medical, surgical interventions, and possibly, in the future, tissue- engineering or cellular or gene therapy. Oral phosphodiesterase type 5 inhibitor (PDE5i), which works with sexual stimulation, is an effective medical therapy for ED with an excellent safety profile. Intracavernosal injection or topical application of vasoactive drugs have also been studied. The first inflatable penile prosthesis was introduced in 1973, and current models of inflatable penile prostheses include the AMS 700 series, Coloplast Titan device and Zephyr ZSI device. A patient-activated inflatable penile prosthesis (IPP) provides patients with a means to achieve dependable spontaneity for intercourse.\n\nRigicon has developed a three-piece inflatable penile prosthesis (IPP) (Infla10®) for the treatment of ED. This study is to assess the safety and effectiveness of the Rigicon IPP in treating ED. Clinical literature and preclinical testing, including biocompatibility, device validation and verification, and animal studies support the safety and efficacy of this device for the intended therapy.'}, 'conditionsModule': {'conditions': ['Erectile Dysfunction (ED)'], 'keywords': ['Rigicon', 'Infla10', 'inflatable penile prosthesis', 'penile prosthesis', 'Dynamic', 'erectile dysfunction']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 182, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients implanted with Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis', 'type': 'EXPERIMENTAL', 'description': 'Male subjects 22 years of age and older who are implanted with an Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis for erectile dysfunction.', 'interventionNames': ['Device: Rigicon Infla10® Inflatable Penile Prosthesis (IPP)']}], 'interventions': [{'type': 'DEVICE', 'name': 'Rigicon Infla10® Inflatable Penile Prosthesis (IPP)', 'description': 'Medical Device: Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis\n\n• Other Names: Inflatable Penile Prosthesis (IPP) Treatment: Erectile dysfunction', 'armGroupLabels': ['Patients implanted with Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The primary safety outcome is the proportion of participants free from any device- or procedure-related adverse event of CTCAE Grade ≥2 through 12 months post-procedure, graded per CTCAE v5.0 and IPP-specific mapping.', 'description': 'Success will be concluded if the two-sided 95 percent confidence interval (equivalently, one-sided 97.5 percent) for the 12-month proportion has its lower bound strictly greater than 0.90 as specified in the statistical plan.', 'timeFrame': '12 months'}, {'measure': 'The primary effectiveness endpoint is a binary ""pass"" or ""fail"" objective axial rigidity test, assessed at 12 months.', 'description': 'The objective axial rigidity test will use a calibrated axial-rigidity device to measure vertical displacement of the fully inflated penis under a standardized 650-gram load. ≤15 mm displacement will be counted as a ""pass"".\n\nSuccess will be concluded if the two-sided 95 percent confidence interval for the 12-month success proportion has its lower bound strictly greater than the pre-specified performance goal in the statistical plan.', 'timeFrame': '12 months'}], 'secondaryOutcomes': [{'measure': 'Percentage of patients free from revision or explant surgeries at 12 months.', 'description': 'This secondary endpoint will summarize ""revision- or explant-free survival"" using Kaplan-Meier methods, with participants without an event right-censored at last contact.', 'timeFrame': '12 months'}, {'measure': 'International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score', 'description': 'The Erectile Function (EF) domain of the IIEF-15 questionnaire (Items 1-5 and 15) will be used to assess patient erectile function. Change from baseline in the EF domain total score will be reported at each time point. The questionnaire may be completed remotely via ePRO.\n\nScale / Range: 6-30 points Direction: Higher scores indicate better erectile function. Assessment Schedule: Baseline and Months 3, 6, 12, 18, 24, and 36.', 'timeFrame': 'Baseline (pre-implantation) and Months 3, 6, 12, 18, 24, and 36 post-implantation.'}, {'measure': 'Rosenberg Self-Esteem Scale (RSES) Total Score', 'description': 'The 10-item Rosenberg Self-Esteem Scale (RSES) is a validated self-report instrument used to measure global self-worth by assessing positive and negative feelings about the self. The total RSES score will be used as a secondary endpoint to evaluate change in participant self-esteem and psychosocial well-being following device implantation.\n\nAdministration and scoring: Each item is rated on a 4-point Likert scale (1 = Strongly Disagree to 4 = Strongly Agree). Items 2, 5, 6, 8, and 9 are reverse scored. The total score ranges from 10 to 40, with higher scores indicating greater self-esteem.\n\nAnalysis: Change from baseline in total RSES score will be summarized at each time point as mean ± standard deviation with 95% confidence intervals, and formally tested within the pre-specified hierarchical secondary endpoint sequence.\n\nScale / Range: 10-40 points Direction: Higher scores indicate higher self-esteem (better outcome).', 'timeFrame': 'Baseline (pre-implantation) and Months 3, 6, 12, 18, 24, and 36 post-implantation.'}, {'measure': 'Adverse Events', 'description': 'Descriptive tabulations by system organ class and preferred term, including device-relatedness and seriousness, and rates for typical post-IPP events categorized as AEs, SAEs, and UADEs.', 'timeFrame': '36 months'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria:\n\n1. Male ≥22 years of age.\n2. Diagnosed with erectile dysfunction (impotence).\n3. Agree to receive Infla10® three-piece IPP as an ED treatment.\n4. Willing to complete all protocol required for follow-up visits and tests.\n\nExclusion Criteria:\n\n1. Contraindication to general anesthesia.\n2. Known allergy or sensitivity to product materials as indicated in the device labeling.\n3. Previous penile prosthesis or prior enlargement surgeries\n4. Diagnosed penile sensory neuropathy.\n5. Patients who are receiving immunosuppressive drugs or have a history of kidney transplantation.\n6. Patients who are receiving chemotherapy at the time of enrolment.\n7. Diagnosed with fibrotic disease, such as priapism or Peyronie's disease or Chordee.\n8. Compromised immune system, such as systemic lupus erythematosus, discoid lupus, or scleroderma.\n9. Uncontrolled diabetes (HbA1c ≥ 9.0% \\[≈75 mmol/mol\\], measured within 90 days prior to surgery.\n10. Bleeding disorder or coagulopathy that may in the judgment of the investigator preclude safe procedure.\n11. Active urogenital infection or active skin infection in region of surgery or systemic infection at the time of assessment.\n12. Clinically significant comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal \\[serum creatinine \\> 2.0 mg/dl\\], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or in the judgment of the physician investigator preclude safe procedure.\n13. Lacking manual dexterity or mental abilities necessary to operate the device.\n14. Expected life expectancy \\< two years.\n15. Unwilling or unable to sign the Informed Consent.\n16. Unwilling or unable to comply with the follow-up study requirements.\n17. Psychogenic erectile dysfunction\n18. Currently participating in an investigational drug or another investigational device exemption (IDE) study.\n19. The cognitively challenged subjects and subjects with any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study questionnaires.\n20. Incarcerated subjects\n21. Subjects who are currently using, or who have not previously attempted and failed, standard non-surgical ED therapies including oral or topical treatments."", 'healthyVolunteers': False, 'sex': 'MALE', 'genderBased': True, 'minimumAge': '22 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Zeynep Tin Konukcu', 'role': 'CONTACT', 'phone': '888-202-9790', 'email': 'clinical@rigicon.com'}], 'locations': [{'facility': 'Perito Urology', 'city': 'Coral Gables', 'state': 'Florida', 'zip': '33146', 'country': 'United States', 'geoPoint': {'lat': 25.72149, 'lon': -80.26838}}, {'facility': 'Atlanta Cosmetic Urology', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30305', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': ""Dr. Levine Men's Health"", 'city': 'Chicago', 'state': 'Illinois', 'zip': '60612', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'Kramer Urology', 'city': 'Hyannis', 'state': 'Massachusetts', 'zip': '02601', 'country': 'United States', 'geoPoint': {'lat': 41.65289, 'lon': -70.2828}}, {'facility': 'Premier Medical Group', 'city': 'New Windsor', 'state': 'New York', 'zip': '12553', 'country': 'United States', 'geoPoint': {'lat': 41.47676, 'lon': -74.02375}}, {'facility': 'Washington Heights Urology', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Sun Health Clinic', 'city': 'Arlington', 'state': 'Texas', 'zip': '76017', 'country': 'United States', 'geoPoint': {'lat': 32.73569, 'lon': -97.10807}}, {'facility': 'Vitality Urology Institute', 'city': 'Houston', 'state': 'Texas', 'zip': '77024', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007172', 'term': 'Erectile Dysfunction'}], 'ancestors': [{'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}",False,
"{'identificationModule': {'nctId': 'NCT04624126', 'orgStudyIdInfo': {'id': 'IRB-57222'}, 'organization': {'fullName': 'Stanford University', 'class': 'OTHER'}, 'briefTitle': 'External Device for Erectile Dysfunction (3D-Erect)', 'officialTitle': 'Non-invasive External Device for Erectile Dysfunction (3D-Erect): a Pilot Study', 'acronym': '3D-Erect'}, 'statusModule': {'statusVerifiedDate': '2025-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-07-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-11-03', 'studyFirstSubmitQcDate': '2020-11-09', 'studyFirstPostDateStruct': {'date': '2020-11-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-19', 'lastUpdatePostDateStruct': {'date': '2025-05-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Michael Eisenberg', 'investigatorTitle': 'Associate Professor of Urology', 'investigatorAffiliation': 'Stanford University'}, 'leadSponsor': {'name': 'Stanford University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True, 'isUnapprovedDevice': True, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The aim of this clinical trial is to test the safety and feasibility of a non-invasive 3D-printed external penile device to achieve successful and satisfactory sexual intercourse in men with erectile dysfunction (ED).', 'detailedDescription': 'A clinical trial to test the safety and feasibility of our newly developed non-invasive 3D-printed external penile device for the treatment and recovery of erectile dysfunction.'}, 'conditionsModule': {'conditions': ['Erectile Dysfunction', 'Impotentia Erigendi']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DEVICE_FEASIBILITY', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 9, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': '3D-Erect arm', 'type': 'EXPERIMENTAL', 'description': 'Participants will be asked to use the 3D-printed penile device during their intercourse with partners.', 'interventionNames': ['Device: 3D-Erect']}], 'interventions': [{'type': 'DEVICE', 'name': '3D-Erect', 'description': '3D-printed erectile device for intercourse', 'armGroupLabels': ['3D-Erect arm']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in modified International Index of Erectile Dysfunction score', 'description': 'score 0 to 30 with higher score meaning overall better erectile function', 'timeFrame': 'baseline and up to 1 month post-baseline'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* males \\>18 years old suffering from any cause moderate to severe erectile dysfunction (e.g. ED after radical prostatectomy and/or radiation therapy for prostate cancer and or other pelvic malignancies affecting the sexual potency; emotional and psychological ED; organic vascular and/or metabolic ED etc.)\n* having a female partner willing to participate in the study.\n\nExclusion Criteria:\n\n* not willing to attempt sexual vaginal intercourse with their partner\n* inability to wear/operate the external penile device for any reason', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Michael Eisenberg, MD', 'affiliation': 'Stanford University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Stanford Health Care, Stanford Hospital', 'status': 'RECRUITING', 'city': 'Stanford', 'state': 'California', 'zip': '94305', 'country': 'United States', 'contacts': [{'name': 'Satvir Basran', 'role': 'CONTACT', 'phone': '650-723-0948', 'email': 'sbasran@stanford.edu'}, {'name': 'Francesco Del Giudice, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Tony Chen, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Alex M Kasman, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007172', 'term': 'Erectile Dysfunction'}], 'ancestors': [{'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}",False,
"{'identificationModule': {'nctId': 'NCT03466619', 'orgStudyIdInfo': {'id': 'Khaled Hafez'}, 'organization': {'fullName': 'Tanta University', 'class': 'OTHER'}, 'briefTitle': 'Penile Prosthesis in Patients With Erectile Dysfunction', 'officialTitle': 'Assessment of Safety and Efficacy of Inflatable Penile Prothesis in Patients With Erectile Dysfunction'}, 'statusModule': {'statusVerifiedDate': '2018-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2014-11-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-12-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-12-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-03-09', 'studyFirstSubmitQcDate': '2018-03-14', 'studyFirstPostDateStruct': {'date': '2018-03-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-03-14', 'lastUpdatePostDateStruct': {'date': '2018-03-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Sherief Abd-Elsalam', 'investigatorTitle': 'Investigator', 'investigatorAffiliation': 'Tanta University'}, 'leadSponsor': {'name': 'Tanta University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Erectile dysfunction (ED) is defined as the persistent inability to attain and or maintain an erection sufficient to permit satisfactory sexual performance', 'detailedDescription': 'In the literature, well- designed studies evaluating safety and efficacy of inflatable penile prosthesis (IPP) is lacking. So, this series aimed at investigating this prospectively.'}, 'conditionsModule': {'conditions': ['Erectile Dysfunction']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'inflatable penile prosthesis (IPP)', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'inflatable penile prosthesis (IPP)', 'type': 'EXPERIMENTAL', 'description': 'inflatable penile prosthesis (IPP)', 'interventionNames': ['Device: inflatable penile prosthesis (IPP)']}], 'interventions': [{'type': 'DEVICE', 'name': 'inflatable penile prosthesis (IPP)', 'description': 'inflatable penile prosthesis (IPP)', 'armGroupLabels': ['inflatable penile prosthesis (IPP)'], 'otherNames': ['penile prosthesis (IPP)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of patients with improved erectile dysfunction', 'description': 'The number of patients with improved erectile dysfunction', 'timeFrame': '3 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients complaining of ED with contraindication or failure of medical treatment\n\nExclusion Criteria:\n\n* Patients lacking manual dexterity or mental abilities necessary to operate the pump\n* General contraindications as uncorrectable bleeding tendency', 'healthyVolunteers': False, 'sex': 'MALE', 'genderBased': True, 'genderDescription': 'Males', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Sherief Abd-Elsalam, MD', 'role': 'CONTACT', 'phone': '00201095159522', 'email': 'sheriefabdelsalam@yahoo.com'}], 'overallOfficials': [{'name': 'Khaled Mohamed Hafez Morsy Almekaty, Msc', 'affiliation': 'Urology Department- Tanta University', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Samir Abdelhakim Elgamal, Prof', 'affiliation': 'Urology Department- Tanta University', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Suks Minhas, Prof', 'affiliation': 'Professor of urology University College London Hospital(UCLH)London, UK', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Tanta university - faculty of medicine', 'status': 'RECRUITING', 'city': 'Cairo', 'state': 'Elgharbia', 'country': 'Egypt', 'contacts': [{'name': 'Sherief Abdelsalam, lecturer', 'role': 'CONTACT', 'phone': '00201095159522', 'email': 'Sheriefabdelsalam@yahoo.com'}], 'geoPoint': {'lat': 30.06263, 'lon': 31.24967}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007172', 'term': 'Erectile Dysfunction'}], 'ancestors': [{'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D015917', 'term': 'Penile Prosthesis'}], 'ancestors': [{'id': 'D019736', 'term': 'Prostheses and Implants'}, {'id': 'D004864', 'term': 'Equipment and Supplies'}]}}",False,
"{'identificationModule': {'nctId': 'NCT05558007', 'orgStudyIdInfo': {'id': 'BZ371CLI004'}, 'organization': {'fullName': 'Biozeus Biopharmaceutical S.A.', 'class': 'INDUSTRY'}, 'briefTitle': 'Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients', 'officialTitle': 'Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A in a Gel Applied in Patients That Performed Radical Prostatectomy'}, 'statusModule': {'statusVerifiedDate': '2024-10', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-11-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-01-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-09-22', 'studyFirstSubmitQcDate': '2022-09-23', 'studyFirstPostDateStruct': {'date': '2022-09-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-10-18', 'lastUpdatePostDateStruct': {'date': '2024-10-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Biozeus Biopharmaceutical S.A.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.', 'detailedDescription': 'Prostate cancer remains one of the most prevalent cancer in men. For its treatment, recent technological advances demonstrate that the most effective treatment is the Radical Prostatectomy (RP) procedure. However, although curative for Prostate Cancer, can result in damage to the cavernosal nerves.\n\nThe cavernosal autonomic nerves travel posterolaterally to the prostate to enter the penis and regulate blood flow and hence erection. Thus, damage caused by RP will affect NO tissue release and blood flow regulation, causing erectile dysfunction.\n\nBZ371A has the ability to restore local blood flow regulation by a new and innovative mechanism of action and, therefore, has potential to be a supportive therapy for RP patients (restoring the erectile function).\n\nThus, this study aims to evaluate efficacy, safety and tolerabilty of BZ371A on the recovery of erectile function of patients that were underwent Radical Prostatectomy.'}, 'conditionsModule': {'conditions': ['Erectile Dysfunction Following Radical Prostatectomy', 'Erectile Dysfunction', 'Prostate Cancer', 'Radical Prostatectomy'], 'keywords': ['Erectile Dysfunction', 'Radical Prostatectomy', 'Prostate Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 72, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Daily oral Tadalafil 5mg + Topical Placebo', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical placebo', 'interventionNames': ['Drug: Tadalafil 5mg', 'Drug: Topical Placebo']}, {'label': 'Daily oral placebo + topical BZ371A', 'type': 'EXPERIMENTAL', 'description': 'Patient that underwent Radical Prostatectomy will receive daily oral placebo and topical BZ371A', 'interventionNames': ['Drug: BZ371A', 'Drug: Oral Placebo']}, {'label': 'Daily oral Tadalafil 5mg + topical BZ371A', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical BZ371A', 'interventionNames': ['Drug: Tadalafil 5mg', 'Drug: BZ371A']}], 'interventions': [{'type': 'DRUG', 'name': 'Tadalafil 5mg', 'description': 'Daily oral administration of tadalafil 5mg', 'armGroupLabels': ['Daily oral Tadalafil 5mg + Topical Placebo', 'Daily oral Tadalafil 5mg + topical BZ371A'], 'otherNames': ['Tadalafil']}, {'type': 'DRUG', 'name': 'BZ371A', 'description': 'Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL', 'armGroupLabels': ['Daily oral Tadalafil 5mg + topical BZ371A', 'Daily oral placebo + topical BZ371A']}, {'type': 'DRUG', 'name': 'Oral Placebo', 'description': 'Oral administration of a placebo pill', 'armGroupLabels': ['Daily oral placebo + topical BZ371A']}, {'type': 'DRUG', 'name': 'Topical Placebo', 'description': 'Topical application of 1.5 mL of placebo', 'armGroupLabels': ['Daily oral Tadalafil 5mg + Topical Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Assisted Erectile Function', 'description': 'Measurement of the ability to to have an erection that allows sexual intercourse, under use of medication. This will be assessed by using the IIEF questionnaire, domain A (erectile function section) (IIEF-EF).', 'timeFrame': 'From up to 30 days before Baseline, Baseline, 30 days, 60 days'}], 'secondaryOutcomes': [{'measure': 'Change in successful vaginal intercourse rate', 'description': 'Rate of successful vaginal intercourse will be assessed through question 3 of the SEP (Sexual Encouter Profile) questionnaire.', 'timeFrame': 'From up to 30 days before Baseline, Baseline, 30 days, 60 days'}, {'measure': 'Change in quality of sexual intercourse', 'description': 'Quality of sexual intercourse, through the EDITS questionnaire (Erectile Dysfunction Inventory of Treatment Satisfaction);', 'timeFrame': '30 days, 60 days'}, {'measure': 'Change in penile extension', 'description': 'Penile extension, measured with a ruler.', 'timeFrame': 'Baseline, 30 days, 60 days'}, {'measure': 'Penile Blood flow increase', 'description': 'Increased blood flow, assessed by peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistivity index (RI) assessed by Doppler examination;', 'timeFrame': 'From up to 30 days before Baseline, Baseline, 30 days, 60 days'}, {'measure': 'Adverse effects report', 'description': 'Adverse effects evaluation of compound use and application', 'timeFrame': 'Baseline 30 days, 60 days and 75 days'}, {'measure': 'Physical examination of the applied region', 'description': 'Number of participants with abnormal physical exam findings in the applied region', 'timeFrame': 'From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days'}, {'measure': 'Change in SBP', 'description': 'Change in Systolic Blood Pressure', 'timeFrame': 'From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days'}, {'measure': 'Change in DBP', 'description': 'Change in Diastolic Blood Pressure', 'timeFrame': 'From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days'}, {'measure': 'Change in Heart Rate (HR)', 'description': 'Change in Heart Rate', 'timeFrame': 'From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days'}, {'measure': 'Basal chest electrocardiogram (ECG).', 'description': 'Number of participants with abnormal ECG test results', 'timeFrame': 'From up to 30 days before Baseline, 30 days and 60 days'}, {'measure': 'Blood evaluation', 'description': 'Number of participants with abnormal laboratory test results', 'timeFrame': 'From up to 30 days before Baseline, and 60 days'}, {'measure': 'Urine evaluation', 'description': 'Number of participants with abnormal laboratory test results', 'timeFrame': 'From up to 30 days before Baseline, and 60 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Men between the ages of 40 and 65 years;\n2. Exclusive heterosexual men, regardless of race or social class.\n3. RP due to prostate cancer without metastasis;\n4. RP performed less than 60 days before the screening visit;\n5. Erectile function prior to normal RP, defined as IIEF questionnaire with more than 22 points in domain A;\n6. Stable sexual partner (more than 2 months prior to RP), and intention to maintain the relationship during the study.\n7. Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP.\n\nExclusion Criteria:\n\n1. Prostate cancer in TNM stage classified as T3 or T4.\n2. Perineal and/or open RP;\n3. Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy;\n4. Uncontrolled diabetes at screening visit (HbA1C \\> 10%);\n5. Prior spinal cord injury with lower limb paralysis;\n6. Current male hormone use, or hypogonadism, defined by total testosterone below 8 nmol/L (2300 pg/mL) or total testosterone between 8 and 11 nmol/L (2300 and 3170 pg/mL) and free testosterone \\< 220 pmol/L (\\< 64 ng/dL);\n7. Patients with current depression, characterized by use or need for use of antidepressants.\n8. Presence of genital lesions (such as severe penile fibrosis or Peyronie\'s disease) or active sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, HPV, and others) that impair analysis of local adverse effects on the genitalia;\n9. Use of topical medications in the genital region that may interfere in the IP evaluation, as well as in its absorption or drug interaction;\n10. Possession of penile prosthesis;\n11. History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart diseases (including history of angina and/or heart failure) and nephropathies;\n12. Current use of nitrates, such as propatilnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®);ketoconazole; ritonavir; and rifampicin.\n13. Findings on ECG and/or laboratory tests that, in the Investigator\'s criteria, are considered significant and offer risk to the research volunteer\'s participation or may hinder the study analyses;\n14. BP outside the limits considered safe: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except situations such as ""white coat syndrome"";\n15. Diseases that can cause priapism, such as sickle cell anemia, multiple myeloma, or leukemia;\n16. Histroy of priapism, defined as painful erection from up to 6 hours.\n17. Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or dysabsortive syndrome, or presence of mucus, pus, or blood in the stool;\n18. Known hypersensitivity to tadalafil and/or BZ371A;\n19. History of symptomatic Lactose intolorence such as: the necessity of enzymatic treatment, abdominal distension or diarrhea when ingesting products or supplements with lactose;\n20. Low adhsesion to 5mg Tadalafil use, characterized by the use of \\<80% of the pills between the 30th and 60th day post PR;.\n21. Pregnant or lacting partner.\n22. Partner in childbearing age which does not accept to get exposed to the treatment\n23. Any disease, condition or physical finding that the Investigator considers significant and that increases the risk of the research subject\'s participation or may interfere with the results, including severe debilitating illness, presence of cancer other than prostate cancer, severe mental illness persistent medication abuse;', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '40 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Camilla NR Trindade, PhD', 'role': 'CONTACT', 'phone': '+55(21)2523-9089', 'email': 'camilla.nunes@biozeus.com.br'}], 'overallOfficials': [{'name': 'Luiz Otávio Torres, Dr', 'affiliation': 'Hospital Urológica', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Hospital Urológica', 'status': 'RECRUITING', 'city': 'Belo Horizonte', 'country': 'Brazil', 'contacts': [{'name': 'Luiz Otávio Torres, Dr.', 'role': 'CONTACT', 'phone': '3190737299', 'email': 'contatoestudo2023@gmail.com'}], 'geoPoint': {'lat': -19.92083, 'lon': -43.93778}}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02', 'submissionTracking': {'estimatedResultsFirstSubmitDate': '2025-07-18', 'submissionInfos': [{'releaseDate': '2025-07-18', 'resetDate': '2025-08-05'}, {'releaseDate': '2025-08-21', 'resetDate': '2025-09-09'}]}}, 'conditionBrowseModule': {'meshes': [{'id': 'D007172', 'term': 'Erectile Dysfunction'}, {'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068581', 'term': 'Tadalafil'}], 'ancestors': [{'id': 'D002243', 'term': 'Carbolines'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D026121', 'term': 'Indole Alkaloids'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006575', 'term': 'Heterocyclic Compounds, 3-Ring'}]}}",False,"{'annotationModule': {'unpostedAnnotation': {'unpostedResponsibleParty': 'Biozeus Biopharmaceutical S.A.', 'unpostedEvents': [{'type': 'RELEASE', 'date': '2025-07-18'}, {'type': 'RESET', 'date': '2025-08-05'}, {'type': 'RELEASE', 'date': '2025-08-21'}, {'type': 'RESET', 'date': '2025-09-09'}]}}}"
"{'identificationModule': {'nctId': 'NCT05100654', 'orgStudyIdInfo': {'id': 'IRB19-1757'}, 'organization': {'fullName': 'University of Chicago', 'class': 'OTHER'}, 'briefTitle': 'Collaborative Urological Prosthetics Investigation Directive Research Group', 'officialTitle': 'Collaborative Urological Prosthetics Investigation Directive Research Group', 'acronym': 'CUPID'}, 'statusModule': {'statusVerifiedDate': '2025-03', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-04-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-01-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-09-30', 'studyFirstSubmitQcDate': '2021-10-19', 'studyFirstPostDateStruct': {'date': '2021-10-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-05', 'lastUpdatePostDateStruct': {'date': '2025-03-10', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Chicago', 'class': 'OTHER'}, 'collaborators': [{'name': 'Loyola University', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine if an additional 6 days of oral antibiotics decreases the risk of penile prosthesis infection after implantation.', 'detailedDescription': 'Erectile dysfunction is a common problem and the incidence increases with age. Penile prosthesis placement for medication refractory erectile dysfunction is well established with high success rates. However, infection remains a dreaded complication with significant patient morbidity requiring device explant. Device innovations such as antibiotic coating and adaptations in technique have led to device infection rate reduction to \\~1-3% in the hands of high volume implanters in modern series. The study team will perform a non-inferiority trial of post-operative antibiotic prophylaxis for IPP procedures with InhibiZonetm coated AMS 700 devices to confirm the hypothesis that a prolonged postoperative antibiotic regimen does not influence infection-related outcomes in de-novo IPP placement. The study team will determine potential risk factors for prosthetic infections and which patients would benefit from an extended post-operative oral antibiotic course of 6 days along with other objectives.'}, 'conditionsModule': {'conditions': ['Erectile Dysfunction', 'Penile Prosthesis Infection'], 'keywords': ['Erectile Dysfunction']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 800, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'No post-operative oral antibiotics', 'type': 'NO_INTERVENTION', 'description': 'Patients will only receive 24hr of IV peri-operative antibiotics'}, {'label': '6 days of oral antibiotics', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients will receive 24hr of IV peri-operative antibiotics and then 6 days of oral antibiotics', 'interventionNames': ['Drug: Doxycycline', 'Drug: Ciprofloxacin', 'Drug: Augmentin', 'Drug: Bactrim']}], 'interventions': [{'type': 'DRUG', 'name': 'Doxycycline', 'description': 'Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function', 'armGroupLabels': ['6 days of oral antibiotics']}, {'type': 'DRUG', 'name': 'Ciprofloxacin', 'description': 'Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function', 'armGroupLabels': ['6 days of oral antibiotics']}, {'type': 'DRUG', 'name': 'Augmentin', 'description': 'Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function', 'armGroupLabels': ['6 days of oral antibiotics']}, {'type': 'DRUG', 'name': 'Bactrim', 'description': 'Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function', 'armGroupLabels': ['6 days of oral antibiotics']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Additional 6 days of oral antibiotics after Penile prothesis placement does not decrease the risk of device infection leading to surgical intervention', 'description': 'From day of surgery through 1 year we are hoping to show that additional 6 days of oral antibiotics do not decrease the risk of penile prosthesis infection requiring surgical intervention for device removal.', 'timeFrame': '12 months'}], 'secondaryOutcomes': [{'measure': 'Additional 6 days of oral antibiotics after Penile prosthesis placement does not decrease the risk of superficial tissue infections after penile prothesis implantation.', 'description': 'From day of surgery through 1 year we are hoping to show that additional 6 days of oral antibiotics do not decrease the risk of superficial skin infection after penile prosthesis placement.', 'timeFrame': '12 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Males aged 35 to 90 yo with no racial or ethnic restrictions and a diagnosis of erectile dysfunction.\n2. Males clinically indicated for de-novo InhibiZonetm coated AMS 700 devices IPP placement procedure per local clinical guidelines who have elected to pursue penile prosthesis as an ED treatment.\n\nExclusion Criteria:\n\n1. Patients with indwelling foreign body in the urinary tract \\> 24 hours prior to the procedure (i.e. foley catheter). Patients using clean intermittent catheterization will not be excluded.\n2. Prior history of or current symptomatic urethral stricture.\n3. History of cystitis caused by Tuberculosis.\n4. Active Cytoxan/cyclophosphamide therapy or immunosuppressive systemic chemotherapy.\n5. Prior augmentation cystoplasty or cystectomy.\n6. Systemic neuromuscular disease known to affect the lower urinary tract such as Spinal Cord Injury, Multiple Sclerosis or other condition leading to neurogenic bladder.\n7. Antibiotic use within the past 1 week or need for antibiotic management immediately prior to the study.\n8. Cases where patients have had a prior penile prosthesis.\n9. Any protected population (i.e. Prisoners)', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '35 Years', 'maximumAge': '90 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Sarah Faris, MD', 'affiliation': 'University of Chicago Department of Surgery', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Chicago', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'We will share individual participant data that is de-identified available to all qualified investigators', 'infoTypes': ['STUDY_PROTOCOL', 'ICF', 'CSR'], 'timeFrame': 'Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database', 'accessCriteria': 'All qualified investigators who sign appropriate data use agreements with the University of Chicago'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007172', 'term': 'Erectile Dysfunction'}], 'ancestors': [{'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D004318', 'term': 'Doxycycline'}, {'id': 'D002939', 'term': 'Ciprofloxacin'}, {'id': 'D019980', 'term': 'Amoxicillin-Potassium Clavulanate Combination'}, {'id': 'D015662', 'term': 'Trimethoprim, Sulfamethoxazole Drug Combination'}], 'ancestors': [{'id': 'D013754', 'term': 'Tetracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D024841', 'term': 'Fluoroquinolones'}, {'id': 'D042462', 'term': '4-Quinolones'}, {'id': 'D015363', 'term': 'Quinolones'}, {'id': 'D011804', 'term': 'Quinolines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D019818', 'term': 'Clavulanic Acid'}, {'id': 'D002969', 'term': 'Clavulanic Acids'}, {'id': 'D047090', 'term': 'beta-Lactams'}, {'id': 'D007769', 'term': 'Lactams'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D000658', 'term': 'Amoxicillin'}, {'id': 'D000667', 'term': 'Ampicillin'}, {'id': 'D010400', 'term': 'Penicillin G'}, {'id': 'D010406', 'term': 'Penicillins'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D004338', 'term': 'Drug Combinations'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}, {'id': 'D013420', 'term': 'Sulfamethoxazole'}, {'id': 'D000096926', 'term': 'Benzenesulfonamides'}, {'id': 'D013449', 'term': 'Sulfonamides'}, {'id': 'D013424', 'term': 'Sulfanilamides'}, {'id': 'D000814', 'term': 'Aniline Compounds'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D013450', 'term': 'Sulfones'}, {'id': 'D014295', 'term': 'Trimethoprim'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06805513', 'orgStudyIdInfo': {'id': 'AUT16661'}, 'secondaryIdInfos': [{'id': 'AUT16661', 'type': 'OTHER', 'domain': 'Sanofi Identifier'}, {'id': 'U1111-1267-2510', 'type': 'REGISTRY', 'domain': 'ICTRP'}], 'organization': {'fullName': 'Sanofi', 'class': 'INDUSTRY'}, 'briefTitle': 'Actual Use Trial of Tadalafil 5 mg', 'officialTitle': 'Actual Use Trial to Switch Tadalafil 5 mg Tablets From Prescription to Over-the-Counter'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-01-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-01-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-02-28', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-01-17', 'studyFirstSubmitQcDate': '2025-01-27', 'studyFirstPostDateStruct': {'date': '2025-02-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-21', 'lastUpdatePostDateStruct': {'date': '2025-02-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this actual use trial (AUT) is to evaluate if participants can appropriately select and use the study product \\[Cialis over the counter (OTC)\\] using the labeling and the mandatory health survey assessment (HSA) for duration of 4-months.', 'detailedDescription': 'This will be an open-label 4-month AUT of tadalafil 5 mg tablet in men who are interested in an OTC treatment for erectile dysfunction. The open-label study will enroll approximately 2,250 participants who qualify for treatment based on the data they enter into the HSA of which an estimated 1000 participants will ultimately proceed to the use phase.'}, 'conditionsModule': {'conditions': ['Erectile Dysfunction']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 2250, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cialis OTC', 'type': 'OTHER', 'description': 'Open Label Single Arm study in men who have the symptoms of ED and who have an interest in an OTC treatment.', 'interventionNames': ['Combination Product: Tadalafil 5 mg tablets with a digital tool.']}], 'interventions': [{'type': 'COMBINATION_PRODUCT', 'name': 'Tadalafil 5 mg tablets with a digital tool.', 'description': 'The combination product will be a Drug (Tadalafil 5 mg) and Health Survey Assessment (as a mandatory digital tool). Tadalafil 5 mg will be taken orally, 1 tablet daily to use for treatment of erectile dysfunction. This study will be conducted remotely, via video interaction.', 'armGroupLabels': ['Cialis OTC'], 'otherNames': ['Cialis 5 mg']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The proportion of inter-dosing intervals in which the recommended time between doses is followed', 'description': 'Dosing intervals from participant dosing occasions as recorded in the eDiary population will be used to calculate this endpoint.', 'timeFrame': 'From the beginning of Use phase to end, at 120 days.'}, {'measure': 'The proportion of all participants found to have a do not use (DNU) condition in the Medical Assessment who also received a DNU Outcome screen in the Health survey assessment', 'timeFrame': '1 day (completion of the enrollment interview)'}], 'secondaryOutcomes': [{'measure': 'Descriptive analysis of care-seeking behaviors in the case of heart attack, priapism, allergic reaction, sudden vision or hearing loss, where the participant took Cialis OTC within the 72 hour time period prior to the event', 'timeFrame': 'From the beginning of Use phase to end, at 120 days.'}, {'measure': 'Descriptive analysis of care-seeking behaviors associated with dizziness or feeling faint which does not get better after sitting or lying down, and where the participant took Cialis OTC within the 72 hour time period prior to the event', 'timeFrame': 'From the beginning of Use phase to end, at 120 days.'}, {'measure': 'Descriptive analysis of serious adverse event (SAE)s and adverse event of special interest (AESI)s.', 'timeFrame': 'From the beginning of Use phase to end, at 150 days (120 days study period + 30 day follow-up period).'}, {'measure': 'Descriptive analysis of dosing behavior patterns among those who do not comply with the recommended dosing interval.', 'timeFrame': 'From the beginning of Use phase to end, at 120 days.'}, {'measure': 'The proportion of participants ever prescribed a nitrate medicine who also received a DNU-Nitrate Outcome screen in the HSA.', 'timeFrame': '1 day (completion of the enrollment interview)'}, {'measure': 'The proportion of all participants found to have ask a doctor before use (AADBU) or ask a doctor or pharmacist before use (AADPBU) conditions in the Medical Assessment who also received an AADBU or AADPBU Outcome screen in the HSA.', 'timeFrame': '1 day (completion of the enrollment interview)'}, {'measure': 'The proportion of participants who take 1 tablet (5 mg) on the first dosing occasion.', 'timeFrame': 'From the beginning of Use phase to end, at 120 days.'}, {'measure': 'The proportion of dosing occasions in which 2 tablets (10 mg) are not exceeded per dosing occasion.', 'timeFrame': 'From the beginning of Use phase to end, at 120 days.'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\nParticipants will be included in Part II (enrolment phase) if they are:\n\n1. Male or female, 16 years of age or older\n2. Living in the US (Since this study will be conducted remotely, it is important to assure that all participants reside in this country.)\n\nParticipants will be included in Part III (use phase) if they:\n\n1. Are male (sex assigned at birth)\n2. Are at least 18 years of age\n3. Complete the HSA with a purchase code for Cialis OTC\n4. Purchase the study product\n\nExclusion Criteria:\n\nBelow participants will be excluded from Part II:\n\n1. Participant lives in the state of Massachusetts (Massachusetts state law requires an application to the State Board of Pharmacy in order to get authorization to distribute the study product to participants who live there.)\n2. Participant 18 years of age or older is unable or unwilling to show a current government-issued identification (ID) in order to verify identity and age\n3. Participant cannot read, speak, and understand English\n4. Participant has participated in another health-related market research study, product label study, or clinical trial in the past 12 months\n5. Participant has ever participated in a research study about a medicine for erectile dysfunction\n6. Participant, or someone else in the household works for a pharmaceutical company\n7. Participant, or someone else in the household is a healthcare professional, works as a part of a health care practice, or has been trained as a healthcare professional\n8. Participant, or someone else in the household is employed by a market research or advertising company\n9. Participant or someone else in the household is employed by PEGUS Research\n10. Participants will be told that if they need corrective lenses to read, they must have them when the remote Enrollment Interview is conducted (Part II). If they do not, they will not be allowed to participate. This exclusion will be implemented during the remote Subgroup Identification Interview (SGI) Interview where the participants will be re-screened.\n11. Participants who are considered minors, according to the law in the state where they reside, who do not have a parent or guardian present and willing to electronically sign permission to allow the minor to participate in the SGI and Enrollment Interviews. A participant is considered a minor in all states if they are 16-17 years of age. Additionally, participants 18 years of age in Alabama or Nebraska, and participants 18-20 years of age in Mississippi are also considered minors.\n12. Participant is not willing or able to attend/participate in the Enrollment Interview remotely\n13. Participant, or someone else in the household, has participated in this study (only one member of each household will be allowed to participate)\n14. Participant does not provide verbal permission to video record study interviews\n15. If necessary to obtain approximately 30% low health literacy (LHL), participants who are not LHL will be screened out\n\nBelow participants will be excluded from Part III:\n\n1. Participants who were not excluded for DNU conditions in the HSA, but were determined in the Medical Assessment to have any of the DNU conditions listed on the DFL\n2. Participants who do not sign the Informed Consent Document (ICD) or if the parent or guardian of a minor does not sign the ICD. (Parent/guardian refusal applies to males who are 18 years of age or older but considered minors in the state where they reside.)\n3. Participants who are unwilling to provide contact information\n4. Participants who are unwilling or unable to use an eDiary to record the required information\n5. Participants who the principal investigator or the Medical Monitor believes should be excluded or removed from further participation in the Use Phase due to safety concerns', 'healthyVolunteers': True, 'sex': 'MALE', 'genderBased': True, 'genderDescription': 'Male', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Trial Transparency email recommended (Toll free for US & Canada)', 'role': 'CONTACT', 'phone': '800-633-1610', 'phoneExt': 'option 6', 'email': 'Contact-US@sanofi.com'}], 'locations': [{'facility': 'Pegus', 'status': 'RECRUITING', 'city': 'Salt Lake City', 'state': 'Utah', 'zip': '84101', 'country': 'United States', 'contacts': [{'name': 'Russell D Bradford, MD', 'role': 'CONTACT', 'phone': '801-487-9899', 'email': 'bradfordr@pegus.com'}], 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': ""Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org""}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007172', 'term': 'Erectile Dysfunction'}], 'ancestors': [{'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068581', 'term': 'Tadalafil'}], 'ancestors': [{'id': 'D002243', 'term': 'Carbolines'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D026121', 'term': 'Indole Alkaloids'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006575', 'term': 'Heterocyclic Compounds, 3-Ring'}]}}",False,
"{'identificationModule': {'nctId': 'NCT02706561', 'orgStudyIdInfo': {'id': '15-317'}, 'organization': {'fullName': 'Memorial Sloan Kettering Cancer Center', 'class': 'OTHER'}, 'briefTitle': 'Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery', 'officialTitle': 'Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery'}, 'statusModule': {'statusVerifiedDate': '2025-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-12-08'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2016-03-03', 'studyFirstSubmitQcDate': '2016-03-07', 'studyFirstPostDateStruct': {'date': '2016-03-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-05-21', 'lastUpdatePostDateStruct': {'date': '2025-05-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Memorial Sloan Kettering Cancer Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'Center for Marital and Sexual Health of South Florida', 'class': 'OTHER'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to test two different ways to help men with sexual rehabilitation.'}, 'conditionsModule': {'conditions': ['Prostate Cancer', 'Erectile Dysfunction'], 'keywords': ['15-317']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 224, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Standard care plus the ACT intervention (ACT-ED)', 'type': 'EXPERIMENTAL', 'description': 'SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)', 'interventionNames': ['Behavioral: questionnaires', 'Behavioral: three in-person sessions', 'Behavioral: monthly phone calls', 'Behavioral: Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)']}, {'label': 'SC plus nurse Enhanced Monitoring and Education (EME)', 'type': 'EXPERIMENTAL', 'description': 'SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).', 'interventionNames': ['Behavioral: questionnaires', 'Behavioral: three in-person sessions', 'Behavioral: monthly phone calls', 'Behavioral: Enhanced Monitoring and Education (EME)']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'questionnaires', 'armGroupLabels': ['SC plus nurse Enhanced Monitoring and Education (EME)', 'Standard care plus the ACT intervention (ACT-ED)']}, {'type': 'BEHAVIORAL', 'name': 'three in-person sessions', 'armGroupLabels': ['SC plus nurse Enhanced Monitoring and Education (EME)', 'Standard care plus the ACT intervention (ACT-ED)']}, {'type': 'BEHAVIORAL', 'name': 'monthly phone calls', 'armGroupLabels': ['SC plus nurse Enhanced Monitoring and Education (EME)', 'Standard care plus the ACT intervention (ACT-ED)']}, {'type': 'BEHAVIORAL', 'name': 'Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)', 'armGroupLabels': ['Standard care plus the ACT intervention (ACT-ED)']}, {'type': 'BEHAVIORAL', 'name': 'Enhanced Monitoring and Education (EME)', 'armGroupLabels': ['SC plus nurse Enhanced Monitoring and Education (EME)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'percentages of patients having an Erectile Function Domain (EFD) total score >= 24', 'description': 'The EFD score of \\>= 24 will be used to indicate ""good"" erectile function. This is both a face valid cut-off, and a cut off that is commonly used in the literature as ""good"" erectile function following radical prostatectomy.', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* As per medical record, early stage prostate cancer (Pathologic Stage 1/2 with Gleason score \\</=8; or Pathologic Stage 3 with Gleason score =/\\< 7)\n* As per medical record, radical prostatectomy (RP) conducted either at MSKCC or at another institution\n* As per medical record, ≤ 9 months post-RP\n* As per medical record, moderate erectile functioning pre-surgery (i.e., 15 or greater on the IIEF Erectile Function Domain (EFD) score, or graded their erections as a 1 or 2 on the standard 5 point Urology Erectile Function scale, or have a score of 6 or greater on the 1-10 pre-surgery erectile function scale on the SMRP assessment or have a total score of 15 or greater on items 2-7 on the Prostrate Quality of Life Survey: Sexual Domain)\n* As per self report or as per medical record starting penile injections as part of the erectile rehabilitation program at MSKCC\n* In the judgment of the consenting professional able to communicate, comprehend, and complete questionnaires in English\n\nExclusion Criteria:\n\n* Both cavernous nerves fully resected as per surgery report (nerve sparing score of 8 in MSKCC surgeon note), or documented in the progress note that the nerves were fully resected.\n* Currently on or has a history of being an Androgen Deprivation Therapy (ADT)\n* Has any indication of Prostate-Specific Antigen (PSA)\n* As per self report, specific injection phobia\n* In the judgment of the consenting professional is unable to provide informed consent and complete study sessions and assessment.\n* As per self report or as documented in the medical record, current untreated (e.g. no medication no therapy) major psychiatric disorder (schizophrenia, major depression). Patients diagnosed with a major psychiatric disorder will be reviewed by the study PI to determine eligibility prior to consent.', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '21 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Christian Nelson, PhD', 'role': 'CONTACT', 'phone': '646-888-0030'}, {'name': 'Andrew Roth, MD', 'role': 'CONTACT', 'phone': '646-888-0024'}], 'overallOfficials': [{'name': 'Chris Nelson, PhD', 'affiliation': 'Memorial Sloan Kettering Cancer Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Memorial Sloan Kettering Cancer Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10065', 'country': 'United States', 'contacts': [{'name': 'Christian Nelson, PhD', 'role': 'CONTACT', 'phone': '646-888-0030'}, {'name': 'Andrew Roth, MD', 'role': 'CONTACT', 'phone': '646-888-0024'}, {'name': 'Christian Nelson, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'Memorial Sloan Kettering Cancer Center', 'url': 'https://www.mskcc.org/'}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}, {'id': 'D007172', 'term': 'Erectile Dysfunction'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D011795', 'term': 'Surveys and Questionnaires'}, {'id': 'D004522', 'term': 'Educational Status'}], 'ancestors': [{'id': 'D003625', 'term': 'Data Collection'}, {'id': 'D004812', 'term': 'Epidemiologic Methods'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D017531', 'term': 'Health Care Evaluation Mechanisms'}, {'id': 'D011787', 'term': 'Quality of Health Care'}, {'id': 'D017530', 'term': 'Health Care Quality, Access, and Evaluation'}, {'id': 'D011634', 'term': 'Public Health'}, {'id': 'D004778', 'term': 'Environment and Public Health'}, {'id': 'D012959', 'term': 'Socioeconomic Factors'}, {'id': 'D011154', 'term': 'Population Characteristics'}]}}",False,
